These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27129008)

  • 1. Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men.
    Olsson H; Sandström R; Neijber A; Carrara D; Grundemar L
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):358-64. PubMed ID: 27129008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
    Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males.
    Chik Z; Johnston A; Tucker AT; Chew SL; Michaels L; Alam CA
    Br J Clin Pharmacol; 2006 Mar; 61(3):275-9. PubMed ID: 16487220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Endocr Pract; 2011; 17(4):574-83. PubMed ID: 21454244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
    Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application.
    Yu Z; Gupta SK; Hwang SS; Cook DM; Duckett MJ; Atkinson LE
    J Clin Pharmacol; 1997 Dec; 37(12):1129-38. PubMed ID: 9506008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application site affects the pharmacokinetics of topical testosterone applied to the axilla compared with the inner arm.
    Davis SR; Evans AM; Humberstone A
    Clin Ther; 2014 Oct; 36(10):1395-401. PubMed ID: 25073836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.
    Wilson DE; Meikle AW; Boike SC; Fairless AJ; Etheredge RC; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):54-9. PubMed ID: 9597560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diclofenac systemic bioavailability of a topical 1% diclofenac + 3% menthol combination gel vs. an oral diclofenac tablet in healthy volunteers: a randomized, open-label, crossover study
.
    Moreira SA; Liu DJ
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):368-372. PubMed ID: 27936526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of testosterone cream applied to scrotal skin.
    Iyer R; Mok SF; Savkovic S; Turner L; Fraser G; Desai R; Jayadev V; Conway AJ; Handelsman DJ
    Andrology; 2017 Jul; 5(4):725-731. PubMed ID: 28334510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men.
    Rolf C; Kemper S; Lemmnitz G; Eickenberg U; Nieschlag E
    Eur J Endocrinol; 2002 May; 146(5):673-9. PubMed ID: 11980623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.